A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

BACKGROUND: Metastatic colorectal cancer (mCRC) has low survival rates. We assessed if addition of veliparib, concurrent to FOLFIRI, improves survival in patients with previously untreated mCRC. METHODS: This study compared veliparib (200 mg BID for 7 days of each 14-day cycle) to placebo, each with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorbunova, Vera, Beck, J. Thaddeus, Hofheinz, Ralf-Dieter, Garcia-Alfonso, Pilar, Nechaeva, Marina, Cubillo Gracian, Antonio, Mangel, Laszlo, Elez Fernandez, Elena, Deming, Dustin A., Ramanathan, Ramesh K., Torres, Alison H., Sullivan, Danielle, Luo, Yan, Berlin, Jordan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342906/
https://www.ncbi.nlm.nih.gov/pubmed/30531832
http://dx.doi.org/10.1038/s41416-018-0343-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342906/
https://www.ncbi.nlm.nih.gov/pubmed/30531832
http://dx.doi.org/10.1038/s41416-018-0343-z

Ejemplares similares